---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027321"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:25:39.382392+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anixa reports final Phase 1 breast cancer vaccine data: 74% immune response, safe, advancing to Phase 2

## Summary
- Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.
- Well tolerated at max tolerated dose; main adverse event was injection-site irritation; no flu-like symptoms.
- Combination with Keytruda generated T cell responses without major additional side effects.
- Enrolled 35 participants across three cohorts: early-stage TNBC, preventive mastectomy, adjuvant Keytruda.
- Planning Phase 2 neoadjuvant combination study with Keytruda in newly diagnosed breast cancer patients.

## SEC filing metadata
- accession: 0001493152-25-027321
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315225027321/0001493152-25-027321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315225027321/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027321
- JSON: https://secwatch.observer/filing/0001493152-25-027321.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.